Stock listing
Frankfurt:20B BioMark Diagnostics, Inc. Aktie
German listing (Frankfurt) of BioMark Diagnostics, Inc. · home listing CSE:BUX
Follow BioMark Diagnostics, Inc. into a list and get an email when it puts out news.
Share price · FWB:20B
€0.244 EUR +0.006 (+2.5%)
Close on Nov 20, 2026
- Day range
- €0.244 – €0.244 EURNov 20, 2026
- Market cap
- €25.98M EURAt the close on Nov 20, 2026 · price × 106.5M shares outstanding
- 52-week range
- €0.191 – €0.416 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €15 EURMedian day 0 shares · 56 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:BUX · Home | $0.40 CAD | -0.02 (-4.8%) | 500 | $0.40 | $0.40 | $0.40 | $0.42 | Close on Nov 20, 2026 |
| OTC:BMKDF | $0.276 USD | -0.021 (-7.2%) | 5,000 | $0.276 | $0.276 | $0.276 | $0.297 | Close on Nov 20, 2026 |
| Frankfurt:20B | €0.244 EUR | +0.006 (+2.5%) | — | €0.244 | €0.244 | €0.244 | €0.238 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:20B · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.263 | +0.001 | +0.4% | €0.262 | €0.263 | €0.262 | 0 | |
| €0.262 | 0.000 | 0.0% | €0.261 | €0.262 | €0.259 | 0 | |
| €0.262 | -0.001 | -0.4% | €0.263 | €0.263 | €0.262 | 0 | |
| €0.263 | -0.011 | -4.0% | €0.274 | €0.275 | €0.261 | 0 | |
| €0.274 | +0.010 | +3.8% | €0.282 | €0.284 | €0.272 | 0 | |
| €0.264 | -0.004 | -1.5% | €0.264 | €0.264 | €0.264 | 0 | |
| €0.268 | -0.012 | -4.3% | €0.276 | €0.283 | €0.267 | 0 | |
| €0.280 | 0.000 | 0.0% | €0.279 | €0.280 | €0.274 | 0 | |
| €0.280 | +0.005 | +1.8% | €0.278 | €0.280 | €0.277 | 0 | |
| €0.275 | -0.003 | -1.1% | €0.275 | €0.275 | €0.270 | 0 | |
| €0.278 | +0.002 | +0.7% | €0.278 | €0.278 | €0.278 | 0 | |
| €0.276 | 0.000 | 0.0% | €0.276 | €0.277 | €0.276 | 0 | |
| €0.276 | -0.001 | -0.4% | €0.274 | €0.278 | €0.272 | 0 | |
| €0.277 | +0.006 | +2.2% | €0.276 | €0.277 | €0.275 | 0 | |
| €0.271 | -0.011 | -3.9% | €0.272 | €0.272 | €0.271 | 0 | |
| €0.282 | -0.002 | -0.7% | €0.282 | €0.282 | €0.282 | 0 | |
| €0.284 | -0.022 | -7.2% | €0.296 | €0.297 | €0.284 | 0 | |
| €0.306 | -0.001 | -0.3% | €0.308 | €0.311 | €0.306 | 0 | |
| €0.307 | 0.000 | 0.0% | €0.307 | €0.307 | €0.307 | 0 | |
| €0.307 | +0.007 | +2.3% | €0.307 | €0.307 | €0.307 | 0 | |
| €0.300 | 0.000 | 0.0% | €0.300 | €0.300 | €0.300 | 0 | |
| €0.300 | -0.013 | -4.2% | €0.300 | €0.300 | €0.300 | 0 | |
| €0.313 | +0.016 | +5.4% | €0.322 | €0.323 | €0.313 | 0 | |
| €0.297 | -0.028 | -8.6% | €0.317 | €0.323 | €0.294 | 0 | |
| €0.325 | -0.002 | -0.6% | €0.325 | €0.325 | €0.325 | 0 | |
| €0.327 | +0.001 | +0.3% | €0.327 | €0.327 | €0.327 | 0 | |
| €0.326 | +0.009 | +2.8% | €0.309 | €0.326 | €0.309 | 0 | |
| €0.317 | 0.000 | 0.0% | €0.313 | €0.322 | €0.309 | 0 | |
| €0.317 | -0.002 | -0.6% | €0.318 | €0.323 | €0.311 | 0 | |
| €0.319 | -0.001 | -0.3% | €0.315 | €0.321 | €0.315 | 0 | |
| €0.320 | +0.026 | +8.8% | €0.309 | €0.321 | €0.309 | 0 | |
| €0.294 | +0.001 | +0.3% | €0.290 | €0.296 | €0.286 | 0 | |
| €0.293 | +0.007 | +2.4% | €0.289 | €0.294 | €0.284 | 0 | |
| €0.286 | -0.002 | -0.7% | €0.288 | €0.289 | €0.285 | 0 | |
| €0.288 | +0.001 | +0.3% | €0.288 | €0.288 | €0.288 | 0 | |
| €0.287 | 0.000 | 0.0% | €0.287 | €0.287 | €0.287 | 0 | |
| €0.287 | -0.002 | -0.7% | €0.281 | €0.290 | €0.281 | 0 | |
| €0.289 | +0.014 | +5.1% | €0.282 | €0.290 | €0.278 | 0 | |
| €0.275 | -0.002 | -0.7% | €0.281 | €0.281 | €0.274 | 0 | |
| €0.277 | +0.003 | +1.1% | €0.281 | €0.284 | €0.277 | 0 | |
| €0.274 | -0.008 | -2.8% | €0.276 | €0.276 | €0.274 | 0 | |
| €0.282 | -0.005 | -1.7% | €0.282 | €0.282 | €0.282 | 0 | |
| €0.287 | +0.007 | +2.5% | €0.281 | €0.292 | €0.281 | 0 | |
| €0.280 | +0.001 | +0.4% | €0.281 | €0.282 | €0.274 | 0 | |
| €0.279 | -0.002 | -0.7% | €0.279 | €0.279 | €0.279 | 0 | |
| €0.281 | -0.001 | -0.4% | €0.281 | €0.281 | €0.281 | 0 | |
| €0.282 | -0.002 | -0.7% | €0.282 | €0.282 | €0.282 | 0 | |
| €0.284 | -0.002 | -0.7% | €0.284 | €0.284 | €0.284 | 0 | |
| €0.286 | +0.003 | +1.1% | €0.284 | €0.288 | €0.283 | 0 | |
| €0.283 | -0.001 | -0.4% | €0.283 | €0.283 | €0.283 | 0 | |
| €0.284 | +0.003 | +1.1% | €0.288 | €0.289 | €0.282 | 0 | |
| €0.281 | -0.001 | -0.4% | €0.286 | €0.288 | €0.280 | 0 | |
| €0.282 | -0.004 | -1.4% | €0.285 | €0.326 | €0.279 | 3,000 | |
| €0.286 | -0.001 | -0.3% | €0.286 | €0.286 | €0.286 | 0 | |
| €0.287 | -0.001 | -0.3% | €0.287 | €0.287 | €0.287 | 0 | |
| €0.288 | -0.048 | -14.3% | €0.288 | €0.288 | €0.288 | 0 | |
| €0.336 | +0.005 | +1.5% | €0.336 | €0.336 | €0.336 | 0 |
- Ticker
- Frankfurt:20B
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 21, 2026
BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
Latest news
BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
Sep 21, 2026
Closed €0.288 (+0.3%) on Sep 21, 2026
BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
Aug 25, 2026
Closed €0.286 (-0.3%) on Aug 25, 2026
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
Jul 31, 2026
Closed €0.325 (+3.2%) on Jul 31, 2026
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
Jun 23, 2026
Closed €0.315 (0.0%) on Jun 23, 2026
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
Apr 14, 2026
Closed €0.345 (-11.8%) on Apr 14, 2026
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
Jan 15, 2026
Closed €0.267 (-1.8%) on Jan 15, 2026
BioMark: 2025 Achievements & 2026 Vision
Dec 31, 2025
Closed €0.267 (-13.0%) on Jan 2, 2026
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
Dec 30, 2025
Closed €0.307 (-1.0%) on Dec 30, 2025
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Dec 23, 2025
Closed €0.298 (+19.2%) on Dec 23, 2025
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Dec 1, 2025
Closed €0.221 (+11.1%) on Dec 1, 2025
BioMark Diagnostics, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 10 in the last 12 months · 22 in all · newest Sep 21, 2026 · oldest 2025
- Decks
- 7 decks · latest September 2025
Where BioMark Diagnostics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:BUX · Home listing | CSE | Canada | CAD |
| OTC:BMKDF | OTC | United States | USD |
| LS Exchange:A12EKB | LS Exchange | Germany | EUR |
| Lang & Schwarz:A12EKB | Lang & Schwarz | Germany | EUR |
| Cboe Canada:BUX | Cboe Canada | Canada | CAD |
| Frankfurt:20B · This page | Frankfurt | Germany | EUR |
| Stuttgart:20B | Stuttgart | Germany | EUR |
Valuation
EV/sales 1,504× against a median of 2.4×: the highest of 10 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $41.81M CAD
- P/E
- Loss
- EV/sales
- 1,504×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 74.6×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P/TSX Composite
- -0.11
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioMark Diagnostics, Inc. · CSE:BUX | US$29.70M | US$29.15M | n/a | 1,504× | n/a | 74.6× | n/a | 0.0× | -0.11 |
| Abnova Taiwan Corp. · TWSE:4133 | US$32.15M | US$20.35M | 23.6× | 1.9× | 13.4× | 0.8× | 13.0% | 0.0× | n/a |
| Precipio, Inc. · NASDAQ:PRPO | US$31.11M | US$27.88M | n/a | 1.0× | 119× | 2.1× | −4.1% | 0.0× | 1.00 |
| Aligned Genetics, Inc. · KRX:238120 | US$31.02M | US$28.31M | 9.0× | 2.4× | 11.8× | 1.1× | 28.7% | 0.3× | n/a |
| ENCell Co., Ltd. · KRX:456070 | US$30.74M | US$14.66M | n/a | 4.7× | n/a | 1.5× | −471.2% | 0.3× | n/a |
| LabTurbo Biotech Corporation · TPEX:7725 | US$29.75M | US$4.98M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Bio Preventive Medicine Corp. · TPEX:6810 | US$29.41M | US$26.21M | n/a | 329× | n/a | 3.7× | n/a | 0.4× | n/a |
| Abingdon Health PLC · LSE:ABDX | US$28.13M | US$26.13M | n/a | 1.8× | n/a | 3.5× | −19.4% | 0.2× | n/a |
| MedMira Inc. · TSXV:MIR | US$26.91M | US$27.23M | n/a | 105× | n/a | n/a | −808.2% | n/a | 0.29 |
| BIOQUAL, Inc. · OTC:BIOQ | US$26.83M | US$42.28M | n/a | 1.1× | n/a | 0.8× | −11.0% | 1.0× | -0.01 |
| Ikonisys SA · EURONEXT:ALIKO | US$26.76M | US$31.12M | n/a | 20.4× | n/a | 1.3× | −302.8% | 0.3× | n/a |
| Median of the others | US$29.58M | US$26.72M | 16.3× | 2.4× | 13.4× | 1.3× | −15.2% | 0.3× | 0.29 |
Team and board
Officers
| Officer | Role |
|---|---|
| Rashid Ahmed Bux | Chief Executive Officer |
| Guoyu Huang | Chief Financial Officer |
| Jean-François Haince | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Ian C.P. Smith | Chair of the Board of Directors |
| Bramhanand Ramjiawan | Director |
| Brian Kai-Ming Cheng | Director |
| James A. Lavender | Director |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2025) | Investor deck | 23 slides | September 2025 |
| Investor Presentation (April 2023) | Investor deck | 42 slides | April 2023 |
| Investor Presentation (July 2022) | Investor deck | 33 slides | July 2022 |
| Investor Presentation (May 2021) | Investor deck | 26 slides | May 2021 |
| Investor Presentation (June 2019) | Investor deck | 32 slides | June 2019 |
| Investor Presentation (June 2016) | Investor deck | 23 slides | June 2016 |
| Investor Presentation (July 2015) | Investor deck | 25 slides | July 2015 |
Financings
| Raise | Date |
|---|---|
| Private placement of units Closed: C$4.26M raised · C$0.3 a unit · Warrants at C$0.5 for 36 months Insiders: Certain insiders, directors and officers subscribed for a portion of the placement Use of proceeds: Commercialization of liquid biopsy tests: lab certification, lab hiring, data security infrastructure and general operating expenses | Mar 31, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.8K | 154.2K | 163.2K | 153.5K | 43.9K | 0 | 263.3K | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | ||||||||
| Gross profit | 0 | 0 | ||||||||
| Research and development | 667.8K | 696.0K | 650.5K | 545.8K | 497.8K | 118.4K | 42.3K | 56.4K | 58.2K | 52.0K |
| Selling, general and administrative | 547.2K | 1.19M | 926.2K | 1.15M | 863.9K | 961.5K | 1.42M | 489.2K | 668.5K | 669.1K |
| Operating income | -1.46M | -2.14M | -1.61M | -1.93M | -1.40M | -1.08M | -1.21M | -545.6K | -726.7K | -721.0K |
| Depreciation and amortization | 382.3K | 401.3K | 393.2K | 386.2K | 179.6K | 13.7K | 11.9K | 11.9K | 11.9K | 11.9K |
| EBITDA | -1.07M | -1.74M | -1.22M | -1.55M | -1.22M | -1.07M | -1.20M | -533.7K | -714.8K | -709.1K |
| Interest expense | 63.3K | 61.5K | 115.2K | 110.2K | 49.7K | 4.14K | 2.39K | 0 | 0 | 0 |
| Income before tax | -1.48M | -1.93M | -1.43M | -1.84M | -1.45M | -1.09M | -1.22M | -545.6K | -726.7K | -715.4K |
| Income tax | 0 | 0 | ||||||||
| Net income | -1.48M | -1.93M | -1.43M | -1.84M | -1.45M | -1.09M | -1.22M | -545.6K | -726.7K | -715.4K |
| Earnings per share, basic | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 619.1K | 2.48M | 156.7K | 72.0K | 382.7K | 877.7K | 611.8K | 20.0K | 36.6K | 17.5K |
| Short-term investments | 391.8K | 0 | ||||||||
| Receivables | 50.3K | 160.7K | 43.0K | 34.4K | 82.1K | 27.2K | 16.1K | 12.6K | 13.3K | 22.1K |
| Current assets | 1.08M | 2.64M | 199.8K | 126.3K | 499.0K | 923.0K | 627.9K | 33.0K | 50.1K | 39.6K |
| Property, plant and equipment | 454.1K | 851.8K | 588.5K | 969.4K | 26.7K | 9.38K | 1.64K | 1.64K | ||
| Total assets | 1.86M | 3.13M | 1.09M | 732.3K | 1.47M | 952.9K | 637.3K | 34.6K | 51.7K | 39.6K |
| Accounts payable | 100.7K | 267.5K | 144.4K | 220.2K | 128.3K | 27.1K | 111.8K | 163.9K | 160.4K | 368.1K |
| Current liabilities | 1.10M | 1.23M | 1.24M | 1.66M | 1.50M | 922.4K | 1.08M | 1.25M | 952.2K | 1.10M |
| Long-term debt | 0 | 96.3K | 91.6K | |||||||
| Total debt | 109.6K | |||||||||
| Total liabilities | 1.53M | 1.39M | 1.70M | 1.88M | 2.11M | 1.03M | 1.08M | 1.25M | 952.2K | 1.10M |
| Shareholders' equity | 331.1K | 1.74M | -609.6K | -1.15M | -635.7K | -79.1K | -439.1K | -1.22M | -900.4K | -1.07M |
| Shares outstanding | 105.1M | 105.1M | 90.9M | 83.3M | 78.0M | 76.8M | 72.3M | 65.0M | 62.8M | 54.4M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.09M | -1.09M | -982.5K | -914.4K | -1.20M | -807.3K | -453.8K | -277.8K | -770.4K | -109.5K |
| Capital spending | -4.23K | -3.53K | -4.39K | -5.30K | -59.2K | -59.2K | -790 | -790 | -1.64K | -1.64K |
| Free cash flow | -1.09M | -1.10M | -986.9K | -919.7K | -1.26M | -455.6K | -454.6K | -277.8K | -772.1K | -111.2K |
| Cash from investing | -3.53K | -4.39K | -5.30K | -59.2K | -3.20K | -790 | -790 | -1.64K | -1.64K | |
| Cash from financing | -377.8K | 3.42M | 1.07M | 609.0K | 768.2K | 1.08M | 1.05M | 261.2K | 791.2K | 112.9K |
| Share buybacks | 3.61M | 1.54M | 640.7K | 235.0K | 911.1K | 871.6K | 222.1K | 753.2K | 147.6K | |
| Change in cash | -1.86M | 2.33M | 84.7K | -310.7K | -495.0K | 265.9K | 591.8K | -16.6K | 19.1K | 3.36K |
Cap table
Built by 6ix from BioMark Diagnostics, Inc.’s releases · as of Jun 30, 2026
- Common shares
- 106,483,435
- Fully diluted
- 106,483,435
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 106,483,435 | Jun 30, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · C$0.50 · expire about Mar 2028 |
Share count over time
| Count | Shares |
|---|---|
| Jun 30, 2026 | 106,483,435 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bramhanand Ramjiawan | Director · Since at least Nov 4, 2026 |
| Brian Kai-Ming Cheng | Director · Since at least Nov 4, 2026 |
| Guoyu Huang | Chief Financial Officer · Since at least Nov 4, 2026 |
| Ian C.P. Smith | Chair of the Board of Directors · Since at least Nov 5, 2026 |
| James Lavender | Director · Since at least Dec 30, 2025 |
| Jean-François Haince | Chief Scientific Officer · Since at least Sep 21, 2026 |
| Rashid Ahmed Bux | Chief Executive Officer · Since at least Sep 21, 2026 |
Log in to ask 6ix AI your own questions about BioMark Diagnostics, Inc.